Day One Biopharmaceuticals, Inc. (DAWN)
NASDAQ: DAWN · Real-Time Price · USD
21.41
+0.01 (0.05%)
Mar 27, 2026, 1:06 PM EDT - Market open
DAWN Stock Forecast
Stock Price Forecast
The 9 analysts that cover DAWN stock have a consensus rating of "Buy" and an average price target of $26, which forecasts a 21.44% increase in the stock price over the next year. The lowest target is $21.5 and the highest is $36.
Price Target: $26 (+21.44%)
Analyst Consensus: Buy
Analyst Ratings
The average analyst rating for DAWN stock is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Oct '25 | Nov '25 | Dec '25 | Jan '26 | Feb '26 | Mar '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 5 | 6 | 6 | 6 | 6 | 4 |
| Buy | 2 | 3 | 3 | 3 | 3 | 1 |
| Hold | 0 | 0 | 0 | 0 | 0 | 5 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 7 | 9 | 9 | 9 | 9 | 10 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| JP Morgan | JP Morgan | Buy → Hold Downgrades $27 → $22 | Buy → Hold | Downgrades | $27 → $22 | +0.42% | Mar 11, 2026 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy → Hold Downgrades $22 → $22 | Strong Buy → Hold | Downgrades | $22 → $22 | +0.42% | Mar 10, 2026 |
| Wedbush | Wedbush | Buy → Hold Downgrades $30 → $22 | Buy → Hold | Downgrades | $30 → $22 | +0.42% | Mar 9, 2026 |
| Jones Trading | Jones Trading | Strong Buy → Hold Downgrades $20 → $22 | Strong Buy → Hold | Downgrades | $20 → $22 | +0.42% | Mar 6, 2026 |
| Needham | Needham | Strong Buy → Hold Downgrades n/a | Strong Buy → Hold | Downgrades | n/a | n/a | Mar 6, 2026 |
Financial Forecast
Revenue This Year
245.23M
from 158.18M
Increased by 55.03%
Revenue Next Year
314.20M
from 245.23M
Increased by 28.12%
EPS This Year
-0.79
from -1.04
EPS Next Year
-0.05
from -0.79
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|
| High | 265.0M | 362.8M | |||
| Avg | 245.2M | 314.2M | |||
| Low | 222.8M | 272.3M |
Revenue Growth
| Revenue Growth | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|
| High | 67.5% | 47.9% | |||
| Avg | 55.0% | 28.1% | |||
| Low | 40.8% | 11.0% |
EPS Forecast
| EPS | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|
| High | -0.07 | 0.56 | |||
| Avg | -0.79 | -0.05 | |||
| Low | -1.98 | -0.62 |
EPS Growth
| EPS Growth | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|
| High | - | - | |||
| Avg | - | - | |||
| Low | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.